Analysis Tools
mortality/aging
|
• in mice challenged with E. coli or LPS
|
immune system
| N |
• mice exhibit normal frequency of T cells, B cells, dendritic cells, NK cells, neutrophils and macrophages in splenocytes; proportion and total numbers of peritoneal macrophages; and in vitro generated bone marrow-derived macrophages IgG3 serum levels are normal
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in mice challenged with LPS, pIpC, TLR ligands or Gram-negative bacteria E. coli
• at 8 months in unchallenged mice
• in mice treated with collagen II
|
|
• in mice challenged with LPS, pIpC, TLR ligands or Gram-negative bacteria E. coli
|
|
• from LPS- or pIpC-stimulated peritoneal macrophages
|
|
• from LPS- or pIpC-stimulated peritoneal macrophages
|
|
• in aged mice
|
|
• mice treated with collagen II exhibit increased ankle joint thickness, more severe swelling in the paws and destruction of cartilage and bone, and increased serum IL6 compared with wild-type mice
|
|
• autoantibody deposition in glomerulus of aged mice
|
|
• in mice challenged with E. coli or LPS
|
|
• membranous glomerulonephritis with more thickened and prominent capillarity loops and autoantibody deposition in glomerulus of aged mice
|
|
• mice challenged with E. coli exhibit increased serum IL6 and TNF, reduced survival, more severe inflammatory hyperemia in the lungs, increased infiltration of mononuclear cells and red blood cells and sepsis compared with wild-type mice
|
|
• in mice challenged with E. coli or LPS
|
renal/urinary system
|
• membranous glomerulonephritis with more thickened and prominent capillarity loops and autoantibody deposition in glomerulus of aged mice
|
respiratory system
|
• severe in mice challenged with E. coli
|
skeleton
|
• mice treated with collagen II exhibit increased ankle joint thickness, more severe swelling in the paws and destruction of cartilage and bone, and increased serum IL6 compared with wild-type mice
|
cardiovascular system
|
• severe in mice challenged with E. coli
|
homeostasis/metabolism
|
• in mice challenged with LPS, pIpC, TLR ligands or Gram-negative bacteria E. coli
• at 8 months in unchallenged mice
• in mice treated with collagen II
|
|
• in mice challenged with LPS, pIpC, TLR ligands or Gram-negative bacteria E. coli
|
hematopoietic system
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
|
• in the serum at 8 months
|
